Next-generation sequencing-based IG clonality analysis to discriminate reactive infiltrates from minimal lymphoma involvement in paired lymphoma and bone marrow biopsies; a EuroClonality-NGS Working Group study

基于新一代测序技术的免疫球蛋白克隆性分析,用于区分配对淋巴瘤和骨髓活检样本中的反应性浸润和轻微淋巴瘤累及;一项 EuroClonality-NGS 工作组研究

阅读:1

Abstract

AIMS: Bone marrow (BM) biopsy is an important procedure in B-cell lymphoma staging. In most biopsies, the presence or absence of a lymphoma infiltrate can reliably be determined by standard histology. However, in a subset of cases with limited infiltration, this assessment remains inconclusive, requiring an alternative approach. Next-generation sequencing (NGS)-based detection of immunoglobulin (IG) gene rearrangements has the potential for resolving these difficult cases because of its high sensitivity. In this study, we tested the NGS-based IG clonality protocol developed by the EuroClonality-NGS Working Group on BM staging biopsies. METHODS AND RESULTS: Forty-nine BM biopsies ranging from morphologically and immunohistochemically evidently involved to negative were analysed and compared to the original lymphoma. A clear distinction in the abundance of overlapping clonal IG rearrangements was observed between BM biopsies that were positive versus negative for lymphoma based on morphology and immunohistochemistry. In the 12 BM biopsies in which morphology and immunohistochemistry were insufficient to differentiate between the presence or absence of lymphoma, the estimated B-cell infiltration ranged from 1% to 5%. In these cases, NGS-based IG clonality analysis of paired primary lymphoma/BM biopsies provided a binary outcome; a subset of cases with hardly or no primary lymphoma-derived IG gene rearrangements in the BM biopsy could be distinguished from cases with clear presence of primary lymphoma-derived IG gene rearrangements. CONCLUSIONS: Our data demonstrated that paired NGS-based IG clonality analysis of lymphoma and BM samples can be a valuable additional tool for difficult BM staging biopsies in patients with B-cell lymphoma.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。